ArticleNPJ Parkinson's disease2026
Peripheral blood transcriptomic signature is associated with cognitive impairment and freezing of gait in Parkinson's disease: a data-driven approach.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a heterogeneous neurodegenerative disorder with variable long-term outcomes. Blood-based biomarkers for prognostic prediction remain underdeveloped. We aimed to develop a peripheral blood transcriptomic signature for predicting long-term complications in PD using unsupervised data-driven methods. Using RNA sequencing data from 541 PD patients and 180 healthy controls from the Parkinson's Progression Markers Initiative (PPMI), we employed weighted gene correlation network analysis (WGCNA) to identify disease-associated gene modules. Contrastive principal component analysis was applied to derive a pseudo-temporal (PT) trajectory score reflecting molecular disease progression. The prognostic value of PT scores was assessed through Cox regression for cognitive impairment, freezing of gait (FOG), wearing-off, and levodopa-induced dyskinesia. WGCNA identified two PD-associated co-expression modules enriched for immune/inflammatory pathways. PT scores derived from these modules showed significant correlations with cognitive, autonomic, and axial motor symptoms. In multivariable Cox regression, higher PT scores independently predicted cognitive impairment (HR = 7.31, P = 0.002) and FOG (HR = 3.43, P < 0.001), but not predominantly dopaminergic motor complications. These findings demonstrate that peripheral blood transcriptomic signatures capture aspects of PD pathophysiology that are not fully explained by nigrostriatal dopaminergic degeneration alone, serving as potential prognostic biomarkers for cognitive impairment and FOG.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.